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Abstract
Para-phenylenediamine (PPD) is a common chromophoric ingredient in oxidative hair-dyes. In some African countries like
Sudan, Egypt and Morocco but also in India this chemical is used alone or in combination with colouring extracts like Henna
for dyeing of the hair or the skin. Excessive dermal exposure to PPD mainly leads to the N-mono- and N,N9-diacetylated
products (MAPPD, DAPPD) by N-acetyltransferase 1 and 2 (NAT1 and 2) catalyzed reactions. Metabolites and PPD are mainly
excreted via renal clearance. Despite a low risk of intoxication when used in due form, there are numerous cases of acute
intoxication in those countries every year. At the ENT Hospital - Khartoum (Sudan) alone more than 300 cases are reported
every year (,10% fatal), mostly caused by either an accidental or intended (suicidal) high systemic exposure to pure PPD.
Intoxication leads to a severe clinical syndrome including laryngeal edema, rhabdomyolysis and subsequent renal failure,
neurotoxicity and acute toxic hepatitis. To date, there is no defined clinical treatment or antidote available and treatment is
largely supportive. Herein, we show the development of a quick on-site identification assay to facilitate differential diagnosis
in the clinic and, more importantly, the implementation of an advanced analytical platform for future in-depth
investigations of PPD intoxication and metabolism is described. The current work shows a sensitive (,25 mM) wet chemistry
assay, a validated MALDI-MS/MS and HPLC-UV assay for the determination of PPD and its metabolites in human urine. We
show the feasibility of the methods for measuring PPD over a range of 50–1000 mM. The validation criteria included linearity,
lower limit of quantification (LLOQ), accuracy and precision, recovery and stability. Finally, PPD concentrations were
determined in clinical urine samples of cases of acute intoxication and the applied technique was expanded to identify
MAPPD and DAPPD in the identical samples.
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Introduction
Since the end of the 19
th century the chemical p-phenylenedi-
amine (PPD) has been described as a hair dye. Up till now it is
used as an ingredient in more than 1000 oxidative hair-dyes in the
US [1,2]. It penetrates into the hair shaft to further undergo
oxidative chemical reactions, resulting in a dark coloration of the
hair. Furthermore, PPD is widely used in the dye-, photographic-
or rubber industries. In addition, in many African countries like
Sudan, Egypt and Morocco, PPD in its pure form or in com-
bination with other natural colouring extracts like Henna (e.g.:
Black Henna) is used for colouring of skin (e.g.: palms and soles)
for cosmetic reasons [3,4]. Unfortunately, in these developing and
other newly industrialized countries (e.g.: India) there are also vast
numbers of unintended and intended incidents of severe to life
threatening intoxication involving this synthetic compound every
year [4,5]. Accidental poisoning is the result of a strong systemic
availability by either ingestion or massive absorption of PPD via
the skin. Moderate dermal exposure to PPD mainly leads to the
N-mono- or N,N9-diacetylated metabolites (MAPPD and DAPPD,
resp.) (Figure 1A) catalyzed by enzymatic reactions of the enzymes
N-acetetyltransferase type 1 and type 2 (NAT1 and 2) [6]. Both
enzymes are important phase II enzymes which are expressed in
various organs including mainly the liver and guts (NAT2) and the
skin (NAT1) facilitating the renal excretion of xenobiotics in
general [6–8]. Other metabolites, like the mono- and diglucur-
onides were hypothesized but have not been confirmed yet [9]. An
abnormal high exposure (intoxication) to PPD leads to saturation
of the NAT1 and NAT2 enzymes resulting in the urinary
excretion of the un-metabolized compound. In addition to the
excretion of PPD, an increased excretion of urochromes might add
to a dark color of the urine, as reported repeatedly in literature
[4,5]. Direct contact of PPD with the epidermis may lead to skin
irritation or allergic reactions [10]. PPD is listed as a contact
allergen by the Centers for Disease Control and Prevention (CDC)
and therefore has no FDA approval for any topical formulation of
cosmetics. With a LD50 of 80 mg/L (determined in rat) but no
proven clinical evidence of causing cancer it is currently not listed
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(e.g.: aniline, which is a chemical degradation product of PPD) are
being discussed as such [11,12]. As initially mentioned, arylamines
occur in the dye industry, in personal care products and cigarette
smoke [13] and their metabolism has been investigated in
numerous studies. Besides the aforementioned NATs, data also
show a major involvement of the CYP1A family in the activation
and detoxification of arylamines [12]. Furthermore, for PPD an
influence on the parasympathetic nervous system has been
described for animal models but has not yet been investigated in
humans [14].
PPD intoxication leads within few hours after exposure to a
severe clinical syndrome including laryngeal edema, rhabdomyol-
ysis and subsequent renal failure, neurotoxicity and acute toxic
hepatitis which per se can lead to dark coloured urine [5]. An
immediate differential diagnosis is crucial to induce an appropriate
and fast supportive treatment including life saving tracheostomy,
antiallergic therapy and forced diuresis, as an antidote is not
available yet. Late diagnosis and delayed treatment potentially
lead to rhabdomyolysis and consequently to kidney failure. Early
clinical manifestations of PPD intoxication symptoms potentially
resemble tropical diseases like malaria, leptospirosis and hepatitis
(jaundice), as well as symptoms of acute poststreptococcal glo-
merulonephritis or haemolytic anaemia.
The current work describes the development and validation of
a Matrix Assisted Laser Desorption/Ionization tandem mass
spectrometry (MALDI-MS/MS) method to quantify urinary PPD
concentrations. The technique allows the possibility to measure
small molecules in large sample sets in a fast, sensitive, precise and
accurate manner [15,16] and to study the correlation of severity
of clinical symptoms and/or treatment progress with urinary
concentrations. Moreover, this technique provides the possibility
to specifically identify the metabolites MAPPD and DAPPD in
urine as shown in the current study. Furthermore, a robust high
performance liquid chromatography method with UV detection
(HPLC-UV) was developed and tested for its feasibility. More-
over, a newly developed wet chemistry assay will allow a simple,
sensitive and cost-efficient test for a fast on-site differential diagnosis
of PPD intoxication in field hospitals using urine samples.
Materials and Methods
Ethics Statement
Sample collection at the Ear, Nose and Throat (ENT) Hospital
of Khartoum was conducted by physicians or qualified personnel,
educated in Good Clinical Practice (GCP) and in close col-
laboration with a medical doctor (EEZ) from the Erasmus MC in
Rotterdam. Urine and plasma samples of cases of suspected PPD
intoxication were collected for on-site diagnostic purposes fol-
lowing an established routine procedure. The samples used for
diagnosis and subsequently for the current investigation were
collected immediately after committal of the patients to the
emergency unit of the clinic in Khartoum. Surplus material was
anonymized prior to shipment to the Netherlands.
The investigation of remaining material was exempted from
review by the Review Board of the Soba University Hospital of
Khartoum, as the study followed a common clinical procedure for
the investigation of rest materials. Consequently, the need for a
written consent by the Ethical committee was waived, due to the
fact that samples were collected on a routine basis and no study
was designed prior to sample collection.
Chemicals
All solvents were of ULC/MS grade and were bought at
Biosolve (Valkenswaard, the Netherlands) unless stated otherwise.
The following chemicals were bought at Sigma Aldrich (Zwijn-
drecht, the Netherlands): chloroform (purity of $99.9%), 2-amino-
5-nitropyridine (ANP), p-phenylenediamine (PPD), a-alpha-cyano-
4-hydroxycinnamic acid, formic acid (FA), diacetoxyiodo-benzene,
phenol, sulfanilic acid and ammonium acetate. Sodium hydroxide
and glacial acetic acid were from Merck (Darmstadt, Germany).
MALDI-QqQ
MALDI-MS/MS analysis was conducted on a FlashQuant
TM
workstation combined with a 4000API triple quadrupole mass
analyzer (MALDI-QqQ; Applied Bioscience/Sciex, Toronto,
Canada).
All measurements were run in multiple reaction monitoring
(MRM) mode unless stated otherwise. The monitored mass
transitions were: PPD m/z 109.2R92.0; ANP m/z 140.2R67.0;
MAPPD m/z 151.4R80.0 and DAPPD 193.4R92.0 (see also
Figure 1A and B). The following settings were used for the
MALDI-MS/MS experiments: laser frequency 1000 Hz, laser
power 90%, laser raster speed 1.0 mm/s. The MALDI target plate
(96well) was maintained at 30 V, skimmer voltage at 0 V and the
CXP (collision cell energy exit potential) was at 20 V. The source
gas and the CAD gas (collision gas) were kept at 10 and 12
(arbitrary units), respectively. The collision energy (CE) for PPD
and the ANP as the internal standard (IS) were kept at 40 V and
25 V, respectively. Measurements were conducted with a dwell
time of 10 ms. a-Cyano-4-hydroxycinnamic acid (CHCA), was
used as MALDI matrix for all measurements. Data were analyzed
with the FlashQuant
TM 1.0 software and Analyst 1.4.2 (Applied
Bioscience/Sciex, Toronto, Canada).
HPLC-UV
Chromatographic separation was carried out on a Dionex
Ultimate system using gradient elution with two solvents: solvent
A, 100% water with 0.01 M ammonium hydroxide (pH 9), solvent
B, 90% methanol with 10% water and 0.01 M ammonium
hydroxide (pH 9). The gradient was initiated at 5% B for 4.5 min,
and subsequently a linear gradient led to 95% B in 5 min, kept for
2 min and brought back to 5% B in 0.5 min. The column was
equilibrated for 3.5 min. Total run time was 16 min.
Figure 1. Chemical structures and respective multiple reaction
monitoring (MRM) transitions of (A) PPD and its metabolites
(MAPPD and DAPPD) and (B) the internal standard (IS) 2-
amino-5-nitropyridine.
doi:10.1371/journal.pone.0022191.g001
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Phenomenex (Aschaffenburg, Germany) was kept at 20uC for the
separation. PPD and ANP (IS) were monitored at a wavelength of
240 nm and 310 nm, respectively. Retention time (Rt) for PPD
was 6.2 min and for the IS 11.0 min. Data were analyzed with the
ChromeleonH v. 6.80 software from Dionex (Sunnyvale, Califor-
nia).
MALDI-TOF
TOF-experiments for the exact mass confirmation of MAPPD
and DAPPD and TOF/TOF experiments for their structural
elucidation were performed on an Ultraflex MALDI-TOF/TOF
mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped
with a 50-Hz nitrogen laser (337 nm). Patient samples were spotted
on a 384well target plate with CHCA as the MALDI matrix. Mass
spectra were recorded in the positive ion reflectron mode.
FlexControl version 2.4 software was used to operate the mass
spectrometer.
Method validation
Stock solutions. A 10 mmol/L PPD stock solution was
prepared by dissolving the pure compound in 10 mL of 0.1% FA
in water. For the calibration standards and quality control (QC)
samples, the stock solution was diluted with 0.1% FA in water.
ANP, used as the internal standard, was dissolved in water and
used at a final concentration of 0.5 mmol/L.
Validation protocol. For the method validation pooled
human urine was used from healthy controls (n=7; age 19–43,
mean 31.6; 4 =,3R). The calibration standards and QC samples
were prepared by mixing 400 mL pooled drug free control urine
from healthy donors with 10 mL of IS, 40 mL 2.1 M sodium
hydroxide solution and 50 mL of diluted PPD stock solution.
The calibration curves consisted of a blank (pure urine), a zero
sample (blank urine spiked with IS) and 7 calibration standards of
PPD at the following concentrations: 50, 100, 150, 250, 500, 750
and 1000 mmol/L for the MALDI-MS/MS analysis and 150, 250,
500, 750 and 1000 mmol/L for the HPLC-UV assay. In both
cases, assay linearity was calculated by using a weighting factor,
previously evaluated by a comparison of the r
2 values and the
determination of the lowest sum of absolute values of the relative
errors between the calculated and the nominal value of each
calibrator (data not shown). For the determination of the LLOQ
for the MALDI-MS/MS, 5 separately prepared samples and 3 for
the determination on the HPLC-UV system were measured at the
respective concentrations. Accuracy and precision measurements
were conducted with three calibration curves on one day (intraday)
and on three consecutive days (interday). For the stability tests
aliquots at three different concentrations (130, 400 and 800 mmol/
L) were prepared in urine and kept for 15 h at room temperature
in the dark, 24 h at +4uC (fridge) and 1 month at 220uC in the
freezer. Recovery was determined on the MALDI-QqQ.
Sample preparation. Liquid/liquid extraction (LLE) was
performed by adding 500 mL of chloroform to the urine sample,
shaken vigorously for 20 s and centrifuged for 2 min at 160006g
to separate the organic layer from the water phase. From the
chloroform layer, 400 mL were transferred to a 1.5 mL Eppendorf
reaction vial. LLE was conducted twice. The combined extracts
were dried in a SpeedVac at 45uC for 20 min.
The dry residue was reconstituted in a 100 mL mixture of
ACN/H2O (50:50 v/v). This solution was injected into the HPLC.
For the MALDI-MS/MS analysis the solution was diluted (106)
with the identical ACN/H2O mixture. This solution was mixed
1:1 with CHCA and 1 mL spotted on a 96well plate (6 spots per
sample).
Wet chemistry assay. The wet chemistry assay was con-
ducted based on the findings described by Verma 1979 and
modified for urine sample [17]. Sample preparation (LLE) was
conducted as described in the preceding paragraph with following
changes to reduce drying time. Two 300 mL steps were chosen for
the extraction. For each step 250 mL of the organic layer were
transferred into a new vial to result in a total volume of 500 mL
for the combined extracts. The extract was dried at 60uC
and reconstituted with 250 mL 2 M sodium hydroxide solution.
200 mL of this solution were transferred to a 96well plate. The
addition of 20 mL of a 1% phenol solution in glacial acetic acid
and 20 mL of a 1% diacetoxyiodo-benzene in glacial acetic acid
resulted in a red color of the solution with concentration
dependent intensity. To prove the linear range of the calibration
curve in the extract from the pooled urine (spiked at the following
concentrations prior to extraction: 0, 25, 50, 100, 250 and
500 mmol/L) a UV spectrum of the highest concentration and a
blank for comparison were recorded using a spectrophotometer.
The absorption maximum was at 450 nm, which was used to
measure the calibrants.
A change in color (in presence of PPD the solution turns red)
was compared to a second extract from the identical patient urine
by adding 20 mL of glacial acetic acid instead of the diacetoxyiodo-
benzene glacial acetic acid solution. This reference solution was
used to show the specificity of the reaction.
Clinical urine samples. Clinical samples (n=15) were
collected, documented and anonymized at the ENT Hospital of
Khartoum (Sudan) in the period between December 2009 and
February 2010. All patients were diagnosed with an intoxication of
PPD and arrived at the clinic within 12 hours after intoxication.
The time interval between urine collection and storage in the
freezer at 220uC was 2–4 hours. Further urine parameters were
measured and collected at the clinic. Patients were between 11 and
41 years old (mean age 25.2+/28.8 years); 13 female and 2 male;
7 of which were in the clinic following a suicide attempt, 2 due to a
homicide, 2 due to an accident and 4 due to an unknown reason.
For the preparation of the patient samples from the clinic,
400 ml of urine were mixed with 10 ml IS, 50 ml of 0.1% FA
followed by 40 mL 2.1 M sodium hydroxide solution prior to LLE.
Results and Discussion
The present study describes the development and validation of a
MALDI-QqQ assay for the determination of PPD in human
urine. Furthermore, it demonstrates a simple and fast possibility to
monitor endogenous metabolites at the same measuring time in
the identical samples, without the necessity of a time consuming
development of a separation. In the current example calculated m/
z values for MAPPD (m/z [M2H]
+ 151) and DAPPD (m/z
[M2H]
+ 193) were identified by a MS1 scan on the MALDI-
QqQ and in a high resolution TOF spectrum of selected patient
samples (see Figure 2). Further structural information for the
confirmation of the metabolites was provided by a MS2 product
ion scan on the MALDI-QqQ and by a TOF/TOF spectrum with
accurate masses (data not shown). Overall the loss of one or two
acetyl groups (242 Da) from MAPPD or DAPPD, the loss of
ammonia (217 Da) and presumably a hydrogen isocyanide
(227 Da) rather than hydrogen cyanide from the PPD after a
loss of one amine function was observed. This conclusion is based
on former studies of Burgers et al. who showed for aniline a
neutral loss of 29 Da as a loss of hydrogen isocyanide [18].
It was demonstrated that MALDI-MS/MS (AB Sciex, Flash-
Quant
TM system) provides an ideal tool to deliver ultrafast (,8s
per sample) and valid data. These results will help to understand
Analytical Investigations of Toxic PPD Levels
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further research to develop a targeted treatment scheme for the
clinic. To facilitate the differential diagnosis in on-site field
hospitals of developing countries we also developed a quick wet
chemistry assay sensitive enough (,25 mmol/L) to compete with
the MALDI-MS/MS assay (LLOQ 50 mmol/L) and therefore
suitable to detect toxicologically relevant urine concentrations by a
simple color test. The development of this assay was based on a
publication by Verma, which describes the detection of various
arylamines in pure solutions leading to different, specific color
changes of the test solution [17]. Some of these compounds
potentially lead to similar color reactions, thus reducing the speci-
ficity of the developed assay. However, to the authors’ knowledge
there is little evidence for such compounds in human urine, which
could interfere with the assay. Metabolism of these compounds is a
further limiting factor for cross reactivity and concentrations of
such chemicals in urine were shown to be below the detection limit
described for the wet chemistry assay in the current work. Aniline,
for example was shown to be below 5 mmol/L in a population
based study by Ku ¨tting et al. [19].
Figure 3A shows a blank urine sample with no color change and
5 spiked concentrations from 25–500 mmol/L and 3 patient
samples with a red color of different intensity, depending on the
PPD concentration. The transmittance of the standards was
measured on a spectrophotometer giving a linear response
(r
2=0.998) from 25–250 mmol/L (see Figure 3B). However, the
highest concentration of 500 mmol/L was outside the linear range
of the measurements. The LLE described in the method protocol
was necessary to visualize the color change in urine samples in the
presence of coloring compounds as described earlier. At this point,
it should be noted that the extraction of a brown colored PPD
stock solution resulted in an extract with a similar color. However,
this was not observed in the dark urine samples. An explanation
for the dark color of some of the urine samples potentially originates
from several sources. For example, jaundice as a result of acute
hepatitis can be observed in patients with PPD intoxication and
leads to a steadily increasing amount of urochromes (urobilinogen,
biliverdin) and bilirubin, that may add to the dark color of the urine
[20]. Similarly rhabdomyolysis may occur and the excretion of
myoglobin may also add to the dark color of the urine [21].
Currently it is unclear to what extent more hydrophilic, oxidized
PPD derivatives form azo-groups (e.g. Bandrowski’s base) and
potentially also add to the color of the urine.
One of the major challenges of the current work was to find an
appropriate IS simultaneously for the MALDI-MS/MS and the
HPLC-UV detection. Several surrogate compounds were tested
for their feasibility, including 2, 5-dihydroxybenzoic acid (DHB),
aniline, acetaminophen (PCM), 4-nitro aniline and salicylamide.
However, these chemicals proved to be unsuitable due to an
increased background for PPD in the MRM mode, instability or
showed to be unreliable. ANP was identified as a suitable IS
(Figure 1B).
Another challenge was the instability of the PPD stock solutions.
For initial experiments in the developmental phase of the assay
PPD was dissolved in pure water. These higher concentrated stock
solutions (10 mmol/L PPD) showed chemical instability (oxidation
processes) in less than 24 hours, which was accompanied by a
visible change of the color to red-brown. However, acidic
conditions (stock solution in 0.1% FA) delayed chemical oxidation
of PPD for two to three days (data not shown). Consequently, fresh
stock solutions were prepared every second day including the stock
solution of the IS.
Figure 2. TOF spectrum (pos. mode) for the identification of two PPD metabolites MAPPD (m/z [M+H]
+ 151) and DAPPD (m/z [M+H]
+
193) in patient urine. Comparative control urine did not show any signals at the corresponding m/z values.
doi:10.1371/journal.pone.0022191.g002
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During the development of the method various sample pre-
paration steps were tested for their feasibility. These tests included
protein precipitation (PPT), solid phase extraction (SPE) and
liquid/liquid extraction (LLE). A simple PPT step with methanol
or acetonitrile (ACN) resulted in recoveries lower than 2%, which
was mainly due to a very high degree of impurities, which
consequently lead to ion suppression during the MALDI-MS/MS
measurements. SPE experiments (polystyrene divinyl benzene or
cyanopropyl) slightly improved PPD recoveries to ,10%.
For the LLE different organic solvents were used and the
highest recovery was found with chloroform. The recovery was
further improved when the pH of the urine sample was adjusted
with NaOH to pH 9 prior to the extraction. Basic conditions push
the equilibrium of protonated and unprotonated PPD into its free
Brønsted-Lowry base, which consequently makes the molecule
more lipophilic. A double LLE with chloroform resulted in
recoveries of ,50% (see Table 1). These results were well in line
with the findings of Meyer et al. 2009 [3].
Method validation
Selectivity. Selectivity was shown for the MALDI-QqQ and
the HPLC-UV. Urine samples from 7 different control donors
were compared on the MALDI-QqQ and peak areas (background)
for the PPD transition (m/z 109.2R92.0; see also Figure 1A) and
the IS transition (m/z 140.2R67.0; see also Figure 1B) showed no
significant difference. Furthermore, the identical samples were
injected into the HPLC and the UV trace did not show any
interfering signals at the retention time of PPD or the IS.
Linearity and LLOQ. The LLOQ was determined at
50 mmol/L for the MALDI-QqQ and at 150 mmol/L (see
Table 1) for the HPLC-UV with a CV,15%, respectively.
Good linearity on the MALDI-QqQ was repeatedly shown over
the invested calibration range of 50–1000 mmol/L (see Figure 4A).
The best fit for the calibration curves was achieved using a
weighting factor of 1/x
2. Higher concentrations (.1000 mmol/L)
resulted in relative errors of the calculated from the nominal
concentration of .25% using linear regression for the results
obtained by MALDI-MS/MS.
The calibration range for the HPLC-UV was determined to be
linear (see Figure 4B) from 150–1000 mmol/L. The best fit for the
calibration curve was achieved using a weighting factor of 1/x
2.
Compared to the MALDI-MS/MS higher concentrations
(.1000 mmol/L) were still in the linear range (data not shown).
Accuracy and Precision. For an assessment of the repro-
ducibility of the assay, inter- (n=3) and intraday accuracy and
precision were determined on three consecutive days. The results
are summarized in Table 2. With one exception for the intraday
precision (24.1%) the overall results were below 20% CV at the
level of the LLOQ and below 15% CV for all other values. The
results for the mean accuracy were always below 17% and showed
no distinct bias of the results. These data depicted a good
reproducibility of the measurements on the MALDI-QqQ.
The repeated measurement (n=3; intraday) of the calibration
curve using HPLC-UV resulted in absolute errors of the accuracy
(bias) below 10% and a CV of below 11% for the precision
(Table 2).
Recovery. Recovery was determined at three different con-
centrations of the calibration range to determine if the concentra-
tion of the PPD in the sample had an influence on the distribution
between the hydrophilic urine and the lipophilic chloroform layer
during the extraction. Recoveries were found as mentioned earlier
to be about 50%, while a slight but not significant increase was
observed at higher concentrations (800 mmol/L) (see Table 1).
Figure 3. Wet chemistry assay for spiked blank and clinical urine samples. (A) Left row bottom to top: urine blank and 5 different spiked
concentrations (25, 50, 100, 250 and 500 mmol/L). Right row top three vials: three clinical samples, which show a positive test result for PPD. (B)
Concentration dependent transmittance (%) from 25–250 mmol/L on a spectrophotometer at 450 nm.
doi:10.1371/journal.pone.0022191.g003
Table 1. Validation results of PPD in human urine.
MALDI MS/MS validation results
Linear range [mmol/L] 50–1000
LLOQ (n=5)[ mmol/L] 50 (CV=14.5%)
Recovery (low/medium/high) 48.7% / 48.9% / 7.7%
Stability [% recovery]
RT (15 h in dark) 98.5%
+46C (24 h) 85.6%
2206C (1 month) 107.9%
MALDI-MS/MS assay: linearity, lower limit of quantification (LLOQ), recovery (at
130, 400 and 800 mmol/L) and stability after addition of formic acid.
doi:10.1371/journal.pone.0022191.t001
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found to have an increased stability in acidic conditions. The pH
of human urine typically ranges from 4.5 to 7.5. The stability of
spiked urine samples was tested at physiological pH at room
temperature, +4uC and at 220uC. Results are summarized in
Table 1. The most striking result was that PPD recoveries dropped
when the urine samples were kept at +4uC for 24 hours. There
was roughly a loss of 15%, strongly emphasizing that during
sample collection in the clinic urine samples need to be frozen at
220uC immediately after collection.
Analysis of clinical samples. To the authors’ knowledge,
this is the first report of the measurement of PPD and its metabolites
in human urine samples from clinical cases of intoxication. For
reasons of speed, sensitivity, selectivity and the possibility to
simultaneously scan for the PPD metabolites, patient measure-
ments were conducted using MALDI-MS/MS. For the HPLC-UV
application a good linearity with a LLOQ of 150 mmol/L was
shown (Figure 4B), allowing the accurate detection of two of the 15
investigated urine samples.
Using the MALDI-MS/MS approach urine samples showed
concentrations up to 324 mmol/L and a mean value of 76 mmol/L
(Figure 5A). Investigations of the metabolites on the same
instrument showed significantly increased values for PPD, MAPPD
and DAPPD compared to the control urine samples. Results are
Figure 4. Calibration curve of PPD (A) on the MALDI-MS/MS system (50–1000 mmol/L) and (B) on the HPLC-UV system (150–
1000 mmol/L). Graphs shows the mean values of (A) 5 and (B) 3 independent measurements and the corresponding r
2 value. Mean +/2 SEM.
doi:10.1371/journal.pone.0022191.g004
Table 2. Validation results of PPD in human urine.
Intra- and interday Accuracy and Precision in human urine
nominal
conc. [mmol/L]
mean calc.
conc.[mmol/L] Accuracy (bias %) Precision (% CV)
MALDI-MS/MS / HPLC-UV MALDI-MS/MS / HPLC-UV
Intra-day (n=3) 1000 960 23.9 2.7 24.1 10.5
750 745 20.6 29.4 9.9 5.2
500 512 2.5 2.2 8.9 8.8
250 261 4.4 9.2 13.2 1.8
150 157 4.5 4.7 2.4 9.4
100 91 28.9 n.d. 9.5 n.d.
50 51 2.1 n.d. 16.2 n.d.
MALDI-MS/MS MALDI-MS/MS
Inter-day (n=3) 1000 894 210.6 8.6
750 768 2.4 7.7
500 516 3.1 10.2
250 231 27.6 13.5
150 175 16.3 12.5
100 100 0.4 8.9
50 48 24.1 17.3
Inter- and intraday accuracy and precision measurements (n=3for each value). The mean relative error of each concentration is expressed as % bias and the
reproducibility is depicted as the coefficient of variation (% CV). Intraday accuracy and precision were also determined on the HPLC-UV system.
doi:10.1371/journal.pone.0022191.t002
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(Figure 5B). Values for the MAPPD showed a larger variance,
including 4 patients with no measurable MAPPD, but DAPPD
values. Consequently, DAPPD could be nicely correlated to PPD
(r
2=0.7618, p=0.001) (see also Figure 5C). Although for instance
Nohynek and colleagues investigated the influence of the NAT2
genotype (slow and intermediate acetylators) after dermal exposure
and saw no significant difference in the metabolite profile of 8
human subjects due to the combined metabolism of the NAT1 and
2 [22], this matter has not yet been investigated after PPD ingestion,
where the primary metabolism will be more influenced by the
NAT2 due to its location in the guts and liver [23].
Conclusion
The current work describes the systematic approach for an in-
depth investigation of PPD intoxication, treatment effects and
metabolism. As a first important step, the current work shows a
simple and quick assay which will greatly support physicians in
hospitals to diagnose patients with PPD intoxication. In addition to
previously described unspecific symptoms, this assay allows for a
fast and cost-efficient identification of the toxin itself in urine
samples by a simple color change. Handling needs no further
technical knowledge and results can be obtained on-site within
30 minutes. With a detection limit of about 25 mmol/L this assay
is roughly as sensitive as the MALDI-QqQ assay, but lacks the
Figure 5. MALDI-MS/MS measurements of urine samples from patients with suspected PPD intoxication and controls. (A) Measured
PPD concentrations in clinical urine samples (n=15); dotted lines show the LLOQ of the MALDI-MS/MS and the HPLC-UV application, resp. (B) Box-
and-whisker blot with the 5–95 percentiles for the comparison of PPD, MAPPD and DAPPD peak areas in drug free control urine (n=5) and clinical
samples of intoxication (n=15). (C) Data correlation (r
2=0.7618) of PPD and DAPPD in patient urine (n=15). Respective p-values are given in the
graphs.
doi:10.1371/journal.pone.0022191.g005
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range. A reliable diagnosis is the first step for a targeted treatment,
which we aim to establish with the help of future investigations of
the intoxication. University hospitals like the one in Khartoum are
the ideal surrounding to collect urine and plasma samples from
cases of identified PPD intoxication. The developed MALDI-MS/
MS application combines a simple sample preparation with a
sophisticated measuring technique, which proved to be an ideal
tool to accurately monitor PPD and both metabolites simulta-
neously. Compared to a common HPLC-UV method (analysis
time 16 min), this mass spectrometry assay is much faster (analysis
time ,8 s) and 3 times more sensitive (see comparison in
Figure 5A), which will be needed in the future to evaluate
pharmacokinetic studies regarding PPD. Furthermore, this
technique is more specific, robust and does not depend on any
kind of separation. Moreover, preliminary data show that the
method can easily be expanded on plasma measurements as we
could identify mainly DAPPD in respective plasma samples (data
not shown). We were not able to identify PPD in plasma which is
well in accordance to the literature where PPD plasma clearance is
described to appear in less than 9 hours, measured in rabbits after
a single dose of 15 mg/kg body weight [24].
The investigated samples are the first report of PPD levels from
patients with a diagnosed PPD intoxication. The data clearly show
the excretion of un-metabolized PPD which correlates with
DAPPD levels and therefore give the rational for further investiga-
tions in urine samples. The simultaneous determination of the toxin
and the metabolites can be used to determine pharmacokinetics in
combination with the development of a first-line treatment before
kidney failure occurs [4]. Despite a few publications regarding
measurements of PPD and its metabolites in biological samples
[1,3,24,25] there is a clear lack of precise information on PPD levels
during the progression of an intoxication, with and without
treatment. Moreover, there are no defined critical or target values
during diagnosis and therapy. Furthermore, these studies will
greatly facilitate the possibilities for the identification of an
appropriate antidote.
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